株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品連続生産の世界市場の予測

Global Pharmaceutical Continuous Manufacturing Market Forecast 2020-2028

発行 Inkwood Research 商品コード 931963
出版日 ページ情報 英文 168 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
医薬品連続生産の世界市場の予測 Global Pharmaceutical Continuous Manufacturing Market Forecast 2020-2028
出版日: 2020年04月13日 ページ情報: 英文 168 Pages
概要

世界の医薬品連続生産市場は、2020年から2028年にかけて8.45%のCAGRで成長すると予測されています。医薬品継続生産システムの普及や、新興国の未開拓市場の成長性、政府およびFDAによる普及促進を図るイニシアチブの拡大、従来の医薬品生産システムに勝る利点などが当市場の成長を促進する見通しです。

当レポートでは、世界の医薬品連続生産市場を調査し、市場の概要、製品・用途・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査範囲と調査手法

  • 調査目的
  • 調査範囲
  • 調査手法
  • 前提と制限

第2章 エグゼクティブサマリー

  • 市場規模と予測
  • 市場概要

第3章 市場力学

  • 市場の定義
  • 成長要因
    • 未開拓の新興市場における開発機会
    • 製薬連続製造システムの採用の増加
    • 連続製造システムの採用に対する政府の取り組みの拡大
  • 阻害要因
    • 顧客の期待の増大
    • 発展途上国における連続製造システムの需要の欠如

第4章 市場分析

  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • 規制の枠組み
  • オポチュニティマトリックス
  • ベンダー情勢
  • 投資洞察

第5章 世界の医薬品連続生産市場:製品別

  • 統合連続システム
  • 半連続システム
  • 制御ソフトウェア

第6章 世界の医薬品連続生産市場:用途別

  • 最終製品製造
  • API(医薬品原薬)製造

第7章 世界の医薬品連続生産市場:エンドユーザー別

  • 製薬企業
  • CMO(医薬品製造受託機関)
  • その他

第8章 世界の医薬品連続生産市場:地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • ベルギー
    • ポーランド
    • その他
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • 韓国
    • タイ
    • インドネシア
    • ベトナム
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第9章 企業プロファイル

  • COPERION GMBH
  • ELI LILLY & COMPANY
  • GEA GROUP AG
  • GEBRUDER LODIGE MASCHINENBAU GMBH
  • GLATT GMBH
  • ホソカワミクロン
  • KORSCH AG
  • L.B. BOHLE MASCHINEN + VERFAHREN GMBH
  • MUNSON MACHINERY COMPANY
  • PFIZER INC
  • SIEMENS HEALTHINEERS
  • SYNTEGON
  • THERMO FISHER SCIENTIFIC INC
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - PHARMACEUTICAL CONTINUOUS MANUFACTURING
  • TABLE 2: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL API MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL API MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, IN 2019
  • FIGURE 6: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, IN 2019
  • FIGURE 10: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, IN 2019
  • FIGURE 13: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2020-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2020-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 17: THE UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 18: CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 20: THE UNITED KINGDOM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: BELGIUM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 27: REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 29: CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 30: JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: AUSTRALIA & NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 34: THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 36: VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: REST OF ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 39: LATIN AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
目次
Product Code: 30916

KEY FINDINGS:

The global pharmaceutical continuous marketing market is anticipated to register a CAGR of 8.45% over the forecast period of 2020-2028. The factors contributing to the growth of the market are the rising adoption of pharmaceutical continuous marketing systems, growth opportunities in unexplored emerging economies, and increasing government initiatives for the adoption of pharmaceutical continuous marketing systems. Further, initiatives taken by the FDA for promoting the use of pharmaceutical CM systems and their advantage over the existing drug manufacturing process are the other crucial factors fueling the market growth.

MARKET INSIGHTS:

Continuous manufacturing is a developed manufacturing process to prepare pharmaceutical products in a short span of time with improved quality, enhanced yield, and lower cost of production. The opportunities offered by the emerging untapped markets are an enhanced pharmaceutical infrastructure, a growing number of pharmaceutical industries, and a surge in demand for pharmaceutical CM systems. The market is categorized into an integrated continuous system, semi-continuous system, and control & software depending on the product. The integrated continuous system dominates the global market in terms of revenue and market share. It is attributed to low cost, time efficiency, high quality of the product productivity, and no manual. However, the higher cost of pharmaceutical manufacturing systems continuous systems hinders the market growth. The intensity of competition in the market is moderate to high, owing to the high growth of the market but low product differentiation.

REGIONAL INSIGHTS:

The global pharmaceutical continuous marketing market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America dominated the market in terms of revenue, and is projected to maintain the trend until the end of the forecast period. This is attributed to major factors such as the presence of well-developed infrastructure in pharmaceutical industries, together with a rise in the use of continuous manufacturing systems, among various other factors.

COMPETITIVE INSIGHTS:

There are many prominent players functioning and registering their presence in the global market, such as Eli Lilly and Company, Hosokawa Micron Corporation, GEA Group, L.B. Bohle Glatt GmbH, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
    • 3.2.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
    • 3.2.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. INCREASING CUSTOMER ANTICIPATIONS
    • 3.3.2. LACK OF DEMAND FOR THE CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY PRODUCT

  • 5.1. INTEGRATED CONTINUOUS SYSTEM
  • 5.2. SEMI-CONTINUOUS SYSTEM
  • 5.3. CONTROL & SOFTWARE

6. MARKET BY APPLICATION

  • 6.1. FINAL DRUG PRODUCT MANUFACTURING
  • 6.2. API MANUFACTURING

7. MARKET BY END-USER

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT MANUFACTURING ORGANIZATIONS
  • 7.3. OTHER END-USERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. THE UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. THE UNITED KINGDOM
    • 8.2.2. FRANCE
    • 8.2.3. GERMANY
    • 8.2.4. ITALY
    • 8.2.5. RUSSIA
    • 8.2.6. BELGIUM
    • 8.2.7. POLAND
    • 8.2.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. INDIA
    • 8.3.4. AUSTRALIA & NEW ZEALAND
    • 8.3.5. SOUTH KOREA
    • 8.3.6. THAILAND
    • 8.3.7. INDONESIA
    • 8.3.8. VIETNAM
    • 8.3.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES

  • 9.1. COPERION GMBH
  • 9.2. ELI LILLY & COMPANY
  • 9.3. GEA GROUP AG
  • 9.4. GEBRUDER LODIGE MASCHINENBAU GMBH
  • 9.5. GLATT GMBH
  • 9.6. HOSOKAWA MICRON CORPORATION
  • 9.7. KORSCH AG
  • 9.8. L.B. BOHLE MASCHINEN + VERFAHREN GMBH
  • 9.9. MUNSON MACHINERY COMPANY
  • 9.10. PFIZER INC
  • 9.11. SIEMENS HEALTHINEERS
  • 9.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
  • 9.13. THERMO FISHER SCIENTIFIC INC